ArticleBlood advances2021
Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy.
Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Survival outcomes in secondary and primary acute lymphoblastic leukemia: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Clonal Hematopoiesis of Indeterminate Potential After Radiation Therapy.International journal of radiation oncology, biology, physics · 2026Article
- Exploration of the clinical exercise physiologist standards in the UK: are they fit for purpose and how could they be developed?BMJ open sport & exercise medicine · 2026Article
- Recurrent clonal radiotherapy-associated fibroepithelial polyp of the pharynx: do low grade radiogenic stromal tumours exist? Case report.Virchows Archiv : an international journal of pathology · 2025Article
- Risks of haematological malignancies in patients treated for solid tumours associated with the use of pegylated granulocyte colony-stimulating factors: A single centre study since 2005.Oncology letters · 2025Article
- Post-cytotoxic myeloid neoplasms: a comprehensive analysis of clinicopathologic, genetic profile, latency determinants, and potential prognostic predictors- a single centre study.Annals of hematology · 2025Article
- Risk of secondary myeloid neoplasms following treatment in patients with grade I-II follicular lymphoma: a retrospective cohort study.Discover oncology · 2025Article
- Therapy-Related Myeloid Neoplasms: Complex Interactions among Cytotoxic Therapies, Genetic Factors, and Aberrant Microenvironment.Blood cancer discovery · 2024Review
- Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study.JCO precision oncology · 2024Article
- Article
- Clinical and molecular response of acute myeloid leukemia harboring non-canonicalHaematologica · 2023Article
- Clinical outcome of therapy-related acute myeloid leukemia patients. Real-life experience in a University Hospital and a Cancer Center in France.Cancer medicine · 2023Article
- Stagnation in quality of next-generation sequencing assays for the diagnosis of hereditary hematopoietic malignancies.Journal of genetic counseling · 2023Article
- Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective.Leukemia · 2023Article
- Progress toward Better Treatment of Therapy-Related AML.Cancers · 2023Review
- Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms.Leukemia research · 2023Article
- Therapy-Related Myeloid Neoplasms: Predisposition and Clonal Evolution.Mediterranean journal of hematology and infectious diseases · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapy-related myeloid neoplasms (t-MNs) are a late complication of cytotoxic therapy and are defined as a distinct entity by the World Health Organization. Although the link between chemotherapy exposure and risk of subsequent t-MN is well described, the association between radiation monotherapy (RT) and t-MN risk is less definitive. We analyzed 109 consecutive patients who developed t-MNs after RT and describe latencies, cytogenetic profile, mutation analyses, and clinical outcomes. The most common cytogenetic abnormality was a clonal abnormality in chromosome 5 and/or 7, which was present in 45% of patients. The median latency from RT to t-MN diagnosis was 6.5 years, with the shortest latency in patients with balanced translocations. One-year overall survival (OS) was 52% and 5-year OS was 22% for the entire cohort. Patients with chromosome 5 and/or 7 abnormalities experienced worse 1-year OS (37%) and 5-year OS (2%) compared with other cytogenetic groups (P < .0001). Sixteen patients underwent net-generation sequencing; ASXL1 and TET2 were the most commonly mutated genes (n = 4). In addition, 17 patients underwent germline variant testing and 3 carried pathogenic or likely pathogenic germline variants. In conclusion, patients with t-MN after RT monotherapy have increased frequencies of chromosome 5 and/or 7 abnormalities, which are associated with poor OS. In addition, pathogenic germline variants may be common in patients with t-MN after RT monotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.